Intrommune Therapeutics Completes Enrollment in the Phase I OMEGA Study for Peanut Allergy

Intrommune Therapeutics, Inc. announced completion of enrollment in the Phase I OMEGA Clinical Study for patients with peanut allergy. The Phase I OMEGA Clinical Trial will be a 48-week trial, including up to 34 weeks of maintenance therapy, in peanut allergic adults.